Armata Pharmaceuticals (ARMP)
(Real Time Quote from BATS)
$2.35 USD
-0.01 (-0.42%)
Updated Sep 24, 2024 10:16 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ARMP 2.35 -0.01(-0.42%)
Will ARMP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ARMP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ARMP
Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Tops Revenue Estimates
ARMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?
Other News for ARMP
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium
Armata Pharmaceuticals Updates Progress and Corporate Presentation
Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
Armata Pharmaceuticals Welcomes David House as New SVP of Finance